The U.S. health regulator has withdrawn emergency-use authorization for AstraZeneca's COVID-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.
about the effectiveness of monoclonal antibodies such as Evusheld against newer variants.
The drugmaker plans to continue to share relevant data with the FDA and other health authorities regarding Evusheld and SARS-CoV-2 variants.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Consulte Mais informação »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Consulte Mais informação »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Consulte Mais informação »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Consulte Mais informação »
With rise of new coronavirus variants, FDA halts authorization of Evusheld | CNNThe US Food and Drug Administration on Thursday halted the emergency use authorization of Evusheld because it does not appear to protect against Covid-19 from viral variants currently circulating in the United States.
Consulte Mais informação »
FDA panel endorses changing primary COVID vaccinesAn FDA expert panel on Thursday unanimously recommended that the U.S. overhaul its pandemic vaccine strategy and replace initial doses of original COVID shots with bivalent ones that target specific Omicron subvariants.
Consulte Mais informação »